PHA Preceptorship Program: A Collaborative Approach for Clinicians on the Front Line

Educational Objectives

The PHA Preceptorship Program is designed to improve competence, performance and patient care practices by instructing front-line clinicians in the highest quality of care for patients with PAH by combining didactic discourse and highly interactive case-based discussion. At the conclusion of this program, participants should be able to:

  • Define key pathophysiologic and epidemiologic components of PAH
  • Accurately diagnose patients through comprehensive screening and early recognition of symptoms
  • Evaluate the patient’s condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center
  • Tailor comprehensive care for complex patient populations

Washington University School of Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.

University of Michigan Medical School

This activity is jointly provided by Washington University School of Medicine in St. Louis, Continuing Medical Education and the Pulmonary Hypertension Association.




Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. United Therapeutics Corporation
This is a program of the PHA Medical Education Fund, made possible through educational grants from our supporters.